TD Cowen Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating
TD Cowen analyst Marc Frahm maintains $Black Diamond Therapeutics(BDTX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 54.7% and a total average return of 18.2%
Piper Sandler Maintains Overweight on Black Diamond Therapeutic, Raises Price Target to $15
Piper Sandler Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Raises Target Price to $15
Piper Sandler analyst Joseph Catanzaro maintains $Black Diamond Therapeutics(BDTX.US)$ with a buy rating, and adjusts the target price from $12 to $15.According to TipRanks data, the analyst has a
US Equity Futures Gain as Investors Search for Fresh Catalysts After Fed Rate Cut
Sector Update: Health Care
Market-Moving News for September 23rd